­­­Smoking reduction trajectories, and their association with smoking cessation: A secondary analysis of longitudinal RCT data

Anthony Barrows [[1]](#footnote-1), Elias Klemperer1, Hugh Garavan1, Nicholas Allgaier1, Nicola Lindson2, Gemma Taylor3

Running Head: SMOKING REDUCTION TRAJECTORIES

Word Count: 3651 of 3500

Primary funding:

NIH/NIDA T32DA045593, NIH/NIGMS P20GM103644. NL is funded by a Cancer Research UK PPRC project grant (PRCPJT-Nov22/100012); the University of Oxford (teaching) and NHS Greater Manchester Integrated Care; GT is funded by a Cancer Research UK Population Researcher Postdoctoral Fellowship award (reference: C56067/A21330) and Cancer Research UK project award (reference: PPRCPJT\100,023). The trials analyzed in this paper were all conducted and funded by McNeil AB, who manufacture nicotine replacement therapy. However, this analysis was not funded by this source and none of the authors receive funding from this source.

Conflicts of interest: GT works for a scientific consulting company offering statistical services for projects unrelated to this research. The current authors were not involved in the design, conduct, analysis, write-up or dissmeniation of the original trials, and the funder of these trials (McNeil AB) had no involvement in the planning, analysis, or interpretation of this secondary analysis.

# ABSTRACT

#### Background and aims

Tobacco smoking remains the leading cause of preventable death worldwide, with quitting the only cure. Smoking reduction can be recommended to people finding it difficult to quit, but evidence on outcomes associated with reduction is mixed.

## Design

Secondary analysis of five randomized placebo-controlled trials of nicotine replacement therapy.

## Setting

Five universities and medical centers in Australia, Europe, and the USA.

## Participants

Adults who smoked daily and were unmotivated to quit. All participants were asked to reduce their smoking.

## Measurements

We determined latent smoking trajectories of participants using average cigarettes per day (CPD) across trial follow-ups (weeks 0, 2, 10, 18, 26). We used predictive modeling, using receiver operating characteristic area under the curve (AUC), to assess associations of trajectories with 52-week smoking cessation.

## Findings

On average, participants smoked CPD (n=2066) at baseline. We selected a three-class trajectory model: Class 1 (n=186) achieved the greatest reduction in CPD (57-90%); Class 2 (n=803) reduced by ~50%; Class 3’s (n=794) CPD remained stable.

Regularized logistic regression models predicting membership to latent classes using baseline characteristics outperformed classification using permuted null distributions (cross-validated AUCs = 0.520 to 0.684, p’s < .01). Older, male participants with lower baseline anxiety were most likely to reduce their smoking.

Latent class improved prediction of smoking cessation at 52-week follow-up over prediction using baseline characteristics by 14.4% (AUC = 0.776 ± 0.010, p = 0.002). Those who reduced their CPD by less than half were nearly 90% less likely to have achieved cessation than those who reduced by over 50% (ORs: Class 1 = 0.111 ± 0.013, Class 3 = 0.070 ± 0.005).

## Conclusions

Findings suggest people who reduce their smoking successfully may be more likely to successfully quit. Therefore, a lack of reduction success could be used as an indicator that greater support is needed to help people to quit. Whether reducing increases the likelihood of quitting, or whether people more able to reduce are more able to quit from the outset is unclear.

# INTRODUCTION

Smoking is the number one cause of premature and preventable illness worldwide (1). Smoking accounts for approximately 5.7% of total health expenditure worldwide and 6.5% in high income countries like the UK and USA (2). Approximately 50% of people who smoke will die unless they quit (3).

Reducing smoking to quit is sometimes recommended to people who have found it difficult to quit smoking abruptly in the past. Though magnitude and duration vary, broadly, smoking reduction is defined as a decrease in the number of cigarettes smoked per day. In the UK and in some parts of Europe, smoking reduction is promoted as a second-line route to quitting smoking or as a harm reduction approach for people who cannot, or may not be ready, to stop smoking completely (4,5). In addition, nicotine replacement therapy (NRT) is licensed for smoking reduction (6). In the USA, smoking reduction is offered informally as part of smoking cessation treatment, and NRT is deemed appropriate for use as a reduction aid (7). There is limited evidence that reduction itself improves health (8), but clearer evidence that smoking reduction is as effective as abrupt quitting in achieving complete cessation (9), which has well established health benefits.

People who smoke report that they perceive smoking reduction as an acceptable way to stop smoking (10–14). Those wishing to reduce their daily number of cigarettes could use a range of different approaches to do so, including a combination of behavioral counseling and NRT (9). Providing behavioral support to reduce to quit may help people to stop smoking more than providing people with self‐help resources only. For example, setting a time period over which to reduce before quitting completely, progressively shortening the time periods in the day when smoking occurs (i.e., timed reduction (15)), or gradually eliminating the easiest to the most difficult cigarettes to give up in a given day (i.e., hierarchical reduction (16)). Other approaches include simply advising people who smoke to reduce their smoking as much as possible without giving any specific guidance on how to do so (17–21). However, there is no clear evidence to support any particular behavioral reduction method over others (9,14).

Where people asked to reduce, but not provided with instructions on how to do so, it is unclear how they choose to do this themselves, e.g. whether they cut down immediately, or later? Whether they steadily reduce smoking until complete cessation? Whether they reduce and then increase the amount smoked? Whether there are other patterns of smoking reduction? Furthermore, are certain patterns of smoking reduction associated with better cessation outcomes, and if so, which ones? Plus, are patterns of smoking reduction determined by participant characteristics or dependency profiles? This information could be important when developing and tailoring smoking reduction interventions and could aid clinicians who recommend and offer smoking reduction treatment.

In this secondary analysis of five randomized placebo-controlled trials of NRT for smoking reduction we:

1. Use latent class analysis (LCA) and machine learning to determine if there are trajectories in cigarettes per day (CPD) overtime in people who are asked to reduce their smoking before quitting, without specific instructions on how to do so.
2. Determine which baseline participant characteristics predict latent class membership.
3. Determine whether latent class membership is associated with biochemically verified smoking cessation, while considering participant characteristics.

Although several studies have used LCA to explore heterogeneity in smoking behavior trajectories (e.g., 17–19), none to date have leveraged contemporary machine learning methods to determine characteristics associated with latent class membership. The present study uses regularized linear models to minimize noise associated with highly correlated predictors while emphasizing effects from relevant predictors of class membership and smoking cessation. These methods focus primarily on overall predictive performance rather than statistical significance.

# METHODS

This study was preregistered on Open Science Framework (22), and all analytical code is available through GitHub (23).

## Study Design

This secondary analysis examined individual-level patient data from five randomized placebo-controlled trials of NRT for smoking reduction (17–19). The trials were carried out to a consistent protocol. Participants were provided with active NRT (inhaler, patches, or gum) in the intervention arms and a placebo form of the same NRT in the control arms. In both arms participants received the same minimal level of behavioral support for smoking reduction and were simply encouraged to reduce their smoking as much as possible, with cessation as the end goal.

The trials were conducted and funded by McNeil AB who manufacture NRT. The current authors were not involved with the original trials, and the funder had no involvement in the planning, analysis, or interpretation of this study.

## Study Details

The trials took place between 1997 and 2003 and were conducted in university and medical centers in Denmark (21), Switzerland (19), Australia (17), the USA (20), and Germany (18). There were 2066 participants enrolled across all five trials. At baseline, all participants were at ≥18 years old, reported smoking ≥15 CPD, were selected because they wanted to reduce but not stop smoking, and had smoked regularly for ≥3 years. Participants were excluded if they were pregnant, breastfeeding, under psychiatric care, deemed to be unfit by a general practitioner, or currently enrolled in a smoking cessation program.

## Data Collection

At baseline, trial investigators gathered data on participants’ demographic details, age started smoking, nicotine dependence (Fagerström Test of Nicotine Dependence; FTND (19)), intention to reduce, intention to quit, smoking history (e.g., number of previous quit attempts, longest period without smoking), self-rated effects from smoking, and the Short Form Health Survey-36 (SF-36/RAND-36, (25–27)). To preserve anonymity, some demographic data were unavailable for this secondary analysis.

Participants also provided a breath carbon monoxide (CO) sample and at baseline and at 2-, 10-, 18-, 26- and 52- weeks from baseline

## Variables

Latent trajectories were determined using percent change from baseline in average CPD at weeks 2, 10, 18, and 26. When CPD was unavailable, participants self-reported cigarettes per week were divided by 7If a participant reported they had stopped smoking, CPD was set to 0. Abstinence at 52 weeks was determined using CO values ≥10 parts per million (ppm).

The baseline variables used to predict latent class were age at trial intake, age started smoking, longest period without smoking, number of previous quit attempts, FTND, intention to quit, length of time since last quit attempt, experience of anxiety in the last 24 hours, experience of depression in the last 24 hours, SF-36 subscales, CO ppm, relief from smoking, study site, and trial treatment group (22 variables).

## Bias

To address bias due to missing data, baseline predictors with greater than 25% missing observations were discarded. Additionally, participants missing ≥7 baseline variables were excluded from analyses. Finally, missing observations for remaining baseline predictors were grouped by study site, sex, and age and imputed using average values within those groups.

## Statistical Methods

### Analysis 1: Trajectories in CPD over time

A latent class mixture model (28–30) was used to determine longitudinal trends in CPD from baseline assessed at trial weeks 2, 10, 18, and 26. The primary dependent variable was percent change in average CPD (e.g., a participant smoking 90% of their baseline level at week 2 received a value of -10% for week 2).

Models ranging from 1 to 6 classes were estimated, and models for classes greater than 1 were initialized using parameters from the 1-class model. Grid search methods were performed for subsequent models, seeking to minimize information criteria at each step. The model that balanced fit and parsimony was selected as optimal.

Posterior classification was used to assign subjects to each latent class using maximum likelihood estimation given the information (i.e., percent change in CPD at each week) collected in the longitudinal model.

### Analysis 2: Predicting longitudinal trajectories in CPD using baseline variables

Elastic net logistic regression (31,32) was used to build predictive models for each latent class using all baseline characteristics as features (i.e., independent variables), and class membership as the target (i.e., dependent variable). Class membership was treated as a binary outcome, with membership to each class predicted using a separate regression model.

Initially, the data were split into 80% training and 20% testing sets. The training data were then used to tune parameters for elastic net logistic regression models. Model selection and evaluation was performed using a nested cross-validation framework. Training was conducted using 5-fold cross validation, with 80% of the training set used for model training and 20% for evaluation. Model hyperparameter selection was conducted using a further divide of this training set using 5-fold cross-validation within each outer fold. Prediction accuracy was measured using receiver operator characteristic (ROC) area-under-the-curve (AUC). Parameters from the model whose AUC results were within one standard error of the optimal cross-validated results were selected (33). For each model, AUC represents the accuracy of prediction of the internal validation set. Hyperparameters from the most successful of these models were used to fit a model to the initial training set to obtain coefficients. To confirm model generalizability, these hyperparameters were also used to fit a final model to the initial testing set. Null ROCs were computed for each predicted class, and overall statistical significance was assessed using AUC’s equivalence with the Mann-Whitney U-statistic (34). This procedure was repeated using each latent class as the target.

### Analysis 3: Which trajectories in CPD predict smoking cessation?

Elastic net linear regression was used to predict smoking abstinence at 1-year follow-up using (1) all baseline characteristics from Analysis 2, and (2) Latent Class (from Analysis 1) in addition to those predictors, and (3) baseline predictors with only subjects in each Latent Class, respectively. The dependent variable was biochemically verified smoking cessation. Participants were counted as having quit smoking if they reported doing so and registered a CO value of < 6ppm (35). All other participants were counted as continuing to smoke. Each regression model was fit and evaluated using nested cross-validation procedures outlined in Analysis 2.

## Quantitative Variables

Ordinal predictors (i.e., longest period without smoking, number of times tried to quit smoking, intention to quit, length of time since last quit attempt, experience of anxiety in the last 24 hours, experience of depression in the last 24 hours, and relief from smoking) were treated as numeric variables. These plus additional numeric predictors (i.e., SF-36 scores, CO, age at intake) and outcomes (i.e., CO-confirmed abstinence at 1-year follow-up) in the training set were normalized and scaled to have a mean of 0 and standard deviation of 1. Numeric predictors in the testing set were normalized blindly using the same transformations as the training set.

# RESULTS

## Participants

Seven subjects were missing baseline CPD values and were not included in analyses. Additionally, 101 subjects were missing 7 or more baseline measures and were not included in analyses. The 1783 remaining subjects had at least one post-baseline average CPD value.

Smoking trajectories were modeled using a total of 5,578 observations (Weeks 2, 10, 19, and 26 had 1764, 1148, 1384, 1282 observations respectively) from 1,783 participants (see flowchart in Figure 1).

## Descriptive Data

Participants were from five countries (Australia, Denmark, Germany, Switzerland, and USA), were 44.8% male (798/1783), with a mean (SD) age of 44.10 (10.72) years and smoked a mean (SD) of 27.32 (9.73) CPD (see Table 1).

Two SF-36 sub score (General and Physical Functioning) values were 20.75% and 21.82% missing respectively and were discarded. Of the remaining missing values (i.e., RSQ pepping-up, calming effects of smoking, and overall last cigarette experience: 7.31%, 2.81%, and 0.05% missing respectively; intention to quit: 2.81%; SF-36 subscales: < 1%), subjects’ ages were categorized into 4 equally sized groups, and all remaining baseline variables were imputed within age-sex-site combinations, using the mean and mode of those combinations where appropriate.

## Analysis 1: Trajectories in cigarettes per day over time

Latent class model-fit information appears in Table 2, suggesting that models using 3-6 classes are optimal. The 3-class model was selected to balance minimal information criteria with parsimony; the 4, 5, and 6-class models did not reveal more information about smoking trajectories. Distributions of CPD changes for each follow-up point and a model-fit curve are available in the supplemental materials.

Class 1 (n = 186, 10.43%) is characterized by an average initial reduction in CPD of approximately 57% at week 2, followed by a trend toward 90% reduction by week 26. Participants in Class 2 (n = 803, 45.04%) initially reduced their smoking approximately 41% and remained consistent, for an average reduction of 46% from baseline at week 26. Class 3 participants (n = 794, 44.53%), in contrast, showed a modest (approximately 22%) reduction in smoking and a return to near-baseline levels (i.e., 6% reduction from baseline) by week 26. Average CPD trajectories for each of the selected 3 classes are shown in Figure 2.

Fixed-effects maximum likelihood estimations show the initial smoking reduction (i.e., change from baseline smoking at week 2) for participants in Class 1 was significantly less than Class 3 (estimate (SE) = -1.31 (0.11), Wald = -12.32, p<.001), but initial smoking reductions among Class 2 participants did not differ from those in Class 3 (estimate (SE) = 0.03 (0.08), Wald = 0.38, p = .701). Within each trajectory, differences in CPD were observed for each week (p’s <.001).

## Analysis 2: Predicting longitudinal trajectories in CPD using baseline variables

Regularized logistic regression models predicting membership to Class 1 vs. all and Class 2 vs. all performed better than chance, while membership to Class 2 vs. all was difficult to discern. The strongest predictive performance is seen predicting Class 1 vs. Class 3 and Class 1 vs. Class 2, while Class 2 vs. Class 3 was within range of chance. During non-parametric statistical comparisons, all models (i.e., one-versus-all and class comparisons) performed significantly better classification using permuted null distributions. See Table 3 for model evaluation and Figure 3a for one-versus-all ROC curves.

To determine the relative contributions of each baseline characteristic to the overall model’s predictive capacity, regression coefficients for each predictor were recorded for each of the 5 outer validation folds. Averages of these coefficients are presented in Figure 4. Participants assigned to Class 1 – those who reduced smoking substantially – tended to be older, have started smoking later in life, and have lower measures of anxiety and nicotine dependence. They were more likely to want to quit smoking at study baseline and to have slightly higher SF-36 social and physical sub scores, but below average pain sub scores. Intuitively, those in Class 1 – the group which reduced its smoking the most – were more likely to have been assigned to the active NRT condition, while those in Class 3 were more likely to have received placebo treatment. Although the greatest number of participants were assigned to Class 2, the model predicting membership to Class 2 showed low overall performance. Consequently, no distinct pattern of features describing Class 2 emerges. Contrasting placebo-assigned subjects in Class 1 with active-assigned subjects in Classes 2 and 3, those with lower baseline anxiety and FTND scores were more likely to reduce smoking without NRT aid, while older, male participants were less likely to reduce despite NRT aid.

Of the 186 participants who reduced their smoking dramatically in Class 1, 61 (32.8%) received placebo NRT during the trial. An additional one-versus-all logistic regression model to predict membership to Class 1 was fit to the 900 (50.5%) participants who received placebo NRT. These participants tended to be male, older at baseline, present with lower anxiety scores, and were more likely to have tried quitting before.

Large site effects were observed. Relative to participants in the USA, participants at the other 4 sites (Switzerland, Germany, Denmark, and Australia) were more likely to follow Class 1’s trajectory and less likely to follow Class 3’s. Additional predictive models were used to determine characteristic patterns associated with individual sites, and no distinct patterns emerged.

## Analysis 3: Which trajectories in CPD predict smoking cessation?

Of the 1783 participants assigned to latent classes, 122 (6.8%) met criteria for biochemically verified smoking cessation (Class 1: 70/186 [37.6%]; Class 2: 34/803 [4.2%]; Class 3: 18/776 [2.3%]) at the 1-year follow-up. Regularized logistic regression was used to predict smoking cessation using baseline characteristics alone (AUC = 0.632 ± 0.006, p < .001), and baseline characteristics plus latent class (AUC = 0.776 ± 0.010, p <.001). Each model outperformed classification using a permuted null distribution. Adding latent class as a predictor improved cessation prediction by 14.4%.

As with the previous analysis, regression coefficients from each model’s validation folds were recorded to assess feature importance in predicting smoking cessation (see Figure 5). In the model using latent class as a predictor, participants in Classes 2 and 3 were approximately 90% less likely to achieve smoking cessation 6 months following the trial than Class 1 (Class 2 OR = 0.111 ± 0.013, Class 3 OR = 0.070 ± 0.005). Participants who received active NRT were also more likely to quit smoking (OR = 1.90 ± 0.157). A large site effect was observed, with participants at sites in Denmark and Germany more likely to quit smoking than those at the USA site.

# DISCUSSION

This study examined smoking patterns in a secondary analysis of five NRT trials and found three distinct repeated measures smoking trajectories among participants who were not motivated to quit smoking at baseline. Approximately 10% of participants initially reduced and nearly or completely eliminated their smoking (Class 1), 45% reduced by approximately half of their baseline CPD and remained at that level throughout the trial (Class 2), and the remaining 45% reduced initially but reverted to cigarette use similar to their baseline levels (Class 3).

Predictive modeling revealed that participants who reduced substantially tended to be older, have later smoking onset, and lower levels of anxiety and nicotine dependence. This trend was emphasized when comparing participants who reduced despite receiving placebo NRT versus those who failed to reduce substantially yet received active NRT. Additionally, regression models using baseline characteristics plus latent class assignment to predict smoking cessation at 52-weeks follow-upoutperformed models including baseline characteristics alone. This suggests that smoking trajectories, including initial patterns of reduction, may have implications for predicting smoking cessation outcomes.

Most importantly, despite random assignment to active or placebo NRT and consistent instructions to reduce smoking, cigarette use trajectories were not homogeneous. In particular, although those who received active NRT were more likely to reduce their smoking, many participants did not reduce. Lower levels of nicotine dependence and anxiety predicted reduction, even among those given placebo NRT.

Consistent with prior research (36,37), those who failed to reduce their smoking during the trial or who only cut out a small number of cigarettes were less likely to have quit smoking following the trial. Although reduction and cessation patterns aligned with treatment assignment, baseline reports of anxiety, social functioning, and nicotine dependence were similarly important. Latent class assignment was approximately as strongly associated with follow-up smoking cessation as was random assignment to active or placebo NRT, which suggests that a focus on initial smoking reduction (i.e., as few as two weeks following instructions to reduce) is important when considering who is likely to benefit from a recommendation to reduce smoking among those not ready to quit abruptly and who may need further support to get to this point. Our findings also indicate that those with lower anxiety achieved greater reductions in CPD, suggesting interventions that address anxiety could help to maximize smoking reduction.

When asked to reduce smoking, those with substantial reductions after two weeks may follow paths toward substantial reduction or quitting, while those with minimal initial reductions may revert to their usual smoking levels. These results align with a previous LCA (38) which concluded that people who smoke and are not looking to quit are heterogeneous.

## Strengths and limitations

Several unmeasured variables might confound the associations in question, and we cannot evaluate the impact of residual confounding. For example, ethnicity, education, intention to reduce were either not measured, or not measured consistently across trials. Additionally, the trials did not capture short term changes in CPD that occurred temporarily between measurements, which could have affected outcomes (39). Latent classes were developed based on self-reported CPD. It is possible that participants inaccurately reported their CPD, but it was not possible to biochemically confirm CPD using CO. Although a person may reduce their CPD, they may also inhale their remaining cigarettes more deeply, which could mean that the CO reading does not decrease in-line with the reduction in CPD (40). Furthermore, CO has a half-life of around 4 hours meaning that the magnitude of the measurement is affected by the recency of smoking (35). Therefore, even if a person has reduced their daily CPD overall this would not be reflected in the CO measurement if they had smoked their remaining cigarettes just before the measure was taken.

Conclusion

Our examination of latent trajectories in smoking behavior among a sample of people who were not motivated to quit revealed heterogeneity in smoking patterns. Specifically, three distinct smoking trajectories were identified, each with implications for subsequent smoking or abstinence. These findings provide further evidence that a greater magnitude of reduction is associated with an increased likelihood of smoking cessation among people who, at baseline, were not ready to quit and demonstrate the importance of reduction during the first two weeks after a smoking intervention.

# ACKNOWLEDGEMENTS

This research was supported by NIH/NIDA T32DA043593 and NIH/NIGMS P20GM103644. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

# REFERENCES

1. World Health Organization. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. 2011 [cited 2023 Jan 20]; Available from: https://apps.who.int/iris/handle/10665/44616

2. Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018 Jan;27(1):58–64.

3. Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. The Lancet. 2013 Jan;381(9861):133–41.

4. NICE. National Institute for Clinical Excellence (NICE). Smoking: Harm reduction Public health guideline [PH45] [Internet] [Internet]. 2013. Available from: https://www.nice.org.uk/guidance/ph45

5. European Network for Smoking and Tobacco Prevention. Guidelines for treating tobacco dependence. 2018.

6. Medicine and Healthcare Products Regulatory Agency Committee. Report of the Committee on Safety of Medicines Working Group on Nicotine Replacement Therapy. London; 2005.

7. Fucito LM, Bars MP, Forray A, Rojewski AM, Shiffman S, Selby P, et al. Addressing the Evidence for FDA Nicotine Replacement Therapy Label Changes: A Policy Statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tob Res. 2014 Jul 1;16(7):909–14.

8. Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res. 2007 Jun;9(6):631–46.

9. Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. Cochrane Tobacco Addiction Group, editor. Cochrane Database Syst Rev [Internet]. 2019 Sep 30 [cited 2022 Dec 7];2019(9). Available from: http://doi.wiley.com/10.1002/14651858.CD013183.pub2

10. Beard E, Vangeli E, Michie S, West R. The Use of Nicotine Replacement Therapy for Smoking Reduction and Temporary Abstinence: An Interview Study. Nicotine Tob Res. 2012 Jul;14(7):849–56.

11. Shiffman S, Hughes J, Ferguson S, Pillitteri J, Gitchell J, Burton S. Smokers’ interest in using nicotine replacement to aid smoking reduction. Nicotine Tob Res. 2007 Nov;9(11):1177–82.

12. Schmidt L, Reidmohr A, Harwell TS, Helgerson SD. Prevalence and Reasons for Initiating Use of Electronic Cigarettes Among Adults in Montana, 2013. Prev Chronic Dis. 2014 Nov 20;11:140283.

13. Hughes J R. Smokers who choose to quit gradually versus abruptly. Addiction. 2007 Aug;102(8):1326–7.

14. Lindson N, Michie S, Aveyard P. Exploratory Analyses of the Popularity and Efficacy of Four Behavioral Methods of Gradual Smoking Cessation. Nicotine Tob Res. 2020 Dec 12;22(12):2257–61.

15. Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Kitchens K, Van Vunakis H. The effects of smoking schedules on cessation outcome: Can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol. 1995;63(3):388–99.

16. Brockway BS, Kleinmann G, Edleson J, Gruenewald K. Non-aversive procedures and their effect on cigarette smoking. Addict Behav. 1977 Jan;2(2–3):121–8.

17. Haustein K. A double-blind, randomized, placebo-controlled multicentre trial of a nicotine chewing gum in smoking reduction. Study ID 980-CHC-9021-0013 Unpubl Data. 2001;

18. Batra A, Klingler K, Landfeldt B, Friederich H, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: A double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther. 2005 Dec;78(6):689–96.

19. Bolliger CT. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ. 2000 Aug 5;321(7257):329–33.

20. Rennard S, Glover E, Leischow S, Daughton D, Glover P, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine Tob Res. 2006 Aug 1;8(4):555–64.

21. Wennike P, Danielsson T, Landfeldt B, Westin Å, Tønnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up: Smoking reduction with nicotine gum. Addiction. 2003 Oct;98(10):1395–402.

22. Weyenberg G, Lindson N, Klemperer E, Taylor G. Smoking reduction trajectories, and their association with smoking cessation: A secondary analysis of longitudinal RCT data. 2022 Aug 30 [cited 2023 Apr 24]; Available from: https://osf.io/qh378/

23. Barrows A. mcneil-lca [Internet]. 2023 [cited 2023 Apr 24]. Available from: https://github.com/ajbarrows/mcneil-lca

24. Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J. 1990 Nov;69(11):763–5.

25. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001 Jan;33(5):350–7.

26. Hays RD, Sherbourne CD, Mazel RM. The rand 36-item health survey 1.0. Health Econ. 1993 Oct;2(3):217–27.

27. Hays RD, Prince-Embury S, Chen H. RAND-36 health status inventory. Psychological Corporation San Antonio, TX; 1998.

28. Proust-Lima C, Philipps V, Liquet B. Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The *R* Package **lcmm**. J Stat Softw [Internet]. 2017 [cited 2022 Nov 14];78(2). Available from: http://www.jstatsoft.org/v78/i02/

29. Proust-Lima C, Philipps V, Diakite A, Liquet B. lcmm: Extended Mixed Models Using Latent Classes and Latent Processes [Internet]. 2022. Available from: https://cran.r-project.org/package=lcmm

30. Hagenaars JA, McCutcheon AL, editors. Applied latent class analysis. Cambridge ; New York: Cambridge University Press; 2002. 454 p.

31. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1–22.

32. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. J Stat Softw. 2011;39(5):1–13.

33. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification And Regression Trees [Internet]. 1st ed. Routledge; 2017 [cited 2022 Nov 23]. Available from: https://www.taylorfrancis.com/books/9781351460491

34. Mason SJ, Graham NE. Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: Statistical significance and interpretation. Q J R Meteorol Soc. 2002 Jul 15;128(584):2145–66.

35. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al. Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. Nicotine Tob Res. 2020 Jun 12;22(7):1086–97.

36. Lindson-Hawley N, Shinkins B, West R, Michie S, Aveyard P. Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date?: Does cigarette reduction predict abstinence? Addiction. 2016 Jul;111(7):1275–82.

37. Klemperer EM, Hughes JR. Does the Magnitude of Reduction in Cigarettes Per Day Predict Smoking Cessation? A Qualitative Review. Nicotine Tob Res. 2015 Mar 5;ntv058.

38. Borrelli B, Gaynor S, Tooley E, Armitage CJ, Wearden A, Bartlett YK. Identification of three different types of smokers who are not motivated to quit: Results from a latent class analysis. Health Psychol. 2018 Feb;37(2):179–87.

39. Klemperer EM, Hughes JR, Naud S. Distal Measurements Can Produce False Negative Results: A Prospective Secondary Analysis of a Natural History Study. Nicotine Tob Res. 2019 Nov 19;21(12):1727–30.

40. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction. 2005 Aug;100(8):1074–89.

# Tables

Participant characteristics by assigned latent class.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Full Cohort | Analysis Sample | Class 1 | Class 2 | Class 3 |
| N (%) | 2066 | 1783 (100) | 186 (10.4) | 803 (45.0) | 794 (44.5) |
| Study Site (%) |  |  |  |  |  |
| Australia | 436 (21.1) | 360 (20.2) | 32 (17.2) | 159 (19.8) | 169 (21.3) |
| Denmark | 411 (19.9) | 340 (19.1) | 35 (18.8) | 175 (21.8) | 130 (16.4) |
| Germany | 385 (18.6) | 353 (19.8) | 60 (32.3) | 153 (19.1) | 140 (17.6) |
| Switzerland | 400 (19.4) | 301 (16.9) | 29 (15.6) | 139 (17.3) | 133 (16.8) |
| USA | 434 (21.0) | 429 (24.1) | 30 (16.1) | 177 (22.0) | 222 (28.0) |
| Study Trt. Group = active (%) | 1032 (50.0) | 900 (50.5) | 125 (67.2) | 413 (51.4) | 362 (45.6) |
| Sex = Male (%) | 931 (45.1) | 798 (44.8) | 96 (51.6) | 357 (44.5) | 345 (43.5) |
| Age (mean (SD)) | 43.98 (10.82) | 44.10(10.72) | 45.79 (11.41) | 44.26 (10.52) | 43.53 (10.73) |
| Baseline FTND (mean (SD)) | 6.12 (2.00) | 6.14 (2.00) | 5.60 (2.13) | 6.11 (2.01) | 6.30 (1.94) |
| Baseline CPD (mean (SD)) | 27.26 (9.74) | 27.32 (9.73) | 25.65 (10.37) | 27.42 (9.78) | 27.62 (9.50) |

Table Latent class model fit comparison (n = 1783). \*Selected model. BIC = Bayesian Information Criterion, AIC = Akaike Information Criterion.

| Number of Classes | BIC | AIC | Maximum Log-Likelihood |
| --- | --- | --- | --- |
| 1 | 2102.42 | 2085.97 | -1039.98 |
| 2 | 577.95 | 545.04 | -266.52 |
| 3\* | 43.75 | -5.62 | 11.81 |
| 4 | -36.02 | -101.85 | 62.92 |
| 5 | -87.61 | -169.90 | 99.95 |
| 6 | -116.79 | -215.54 | 125.77 |

# 

Table \*Average AUC across five-fold cross-validation SEM. \*\*AUC using unseen data. p values represent the probability that the test AUC value is greater than the average computed null AUC value for the test data.

|  | Mean CV AUC\* | Test AUC\*\* |  |
| --- | --- | --- | --- |
| Class 1 vs. All |  | 0.766 |  |
| Class 2 vs. All |  | 0.569 |  |
| Class 3 vs. All |  | 0.585 |  |
| Class 1 vs. Class 2 |  | 0.784 |  |
| Class 1 vs. Class 3 |  | 0.788 |  |
| Class 2 vs. Class 3 |  | 0.523 |  |
| Class 1 vs. All (Placebo NRT Only) |  | 0.717 |  |

# Figures

# 

**Figure 1** Participant record availability flowchart. Participants with baseline CPD values at least one follow-up value were included in analysis of smoking trajectories. For smoking cessation analysis, participants missing CO values were assumed to have continued smoking.

Chart, line chart

Description automatically generated

**Figure 2** Average smoking trajectories for the 3-class model (i.e., change from baseline smoking rate) (n = 1783). Error bars represent SD from average CPD at each trial follow-up point.

Chart, histogram

Description automatically generated

­­

**Figure 3** Receiver operating characteristic (ROC) curves for regularized binary logistic regression predictive models. **a.)** Prediction of smoking trajectories as a proportion of baseline smoking during the trial. Each curve represents one-versus-all prediction to latent trajectories 1, 2, and, 3 in turn. The model predicting membership to Class 1, the group who reduced the most, performed best (AUC = 0.657 ± 0.027). All three models performed better than classification using a permuted null distribution (p’s <.001). **b.)** Smoking cessation prediction 6 months after the trial using participant baseline characteristics alone (blue) and baseline characteristics plus latent class as a predictor (red). Adding latent class as a predictor improved classification performance by an average of 14.4% (AUC = 0.776 ± 0.010, p = 0.002), suggesting smoking trajectories among people not looking to quit may be meaningful for long-term cessation outcomes. Each model performed better than classification using a permuted null distribution (p’s <.001).

Table

Description automatically generated

**Figure 4** Feature importance from prediction of class membership using baseline characteristics. Each class was predicted using one-versus-all classification. Values represent mean odds ratios for regularized binary logistic regression coefficients across five outer validation folds. Error bars represent the standard deviations from these averages. Dashed lines represent odds ratios of 1, or no effect. Values to the left of these lines represent decreased odds of membership to a particular latent trajectory, while values to the right represent increased odds. Notably, participants in Class 1 – those who reduced smoking the most – tended to be slightly older, score lower on anxiety symptoms at baseline, and were more likely to be male. As expected, those in Class 1 were more likely to have received active NRT during the trial. In contrast, participants in Class 3 tended to have lower baseline CPD values, score lower on depression symptoms, were more likely to be female, and to have higher baseline nicotine dependence scores. These participants were also more likely to have received placebo NRT during the trial. **Right-most column:** Average feature importance for a binary logistic regression model using only the 900 (50.5%) who received placebo NRT, predicting membership to Class 1, the group which reduced their smoking the most. In this group, older participants presenting with lower anxiety scores, and those who have tried to quit before were more likely to reduce their smoking. Finally, a large site effect is observed, with participants from the German site more likely to reduce, and the Australian site less so.

Table

Description automatically generated with medium confidence

**Figure 5** Feature importance from regularized binary logistic regression models predicting smoking cessation 6 months following the trial. Values represent mean odds ratios for regression coefficients across five outer validation folds, and error bars represent the standard deviations from those values. Dashed lines represent odds ratios of 1, or no effect. Values to the left of the dashed lines represent decreased odds of smoking cessation after the trial, while values to the right represent increased cessation odds. When using latent class as a predictor (left column), latent class becomes one of the predominant associations with smoking cessation (Class 2 OR = 0.111 ± 0.013, Class 3 OR = 0.070 ± 0.005), along with receiving active NRT (OR = 1.90 ± 0.157). A large site effect was observed, with participants at sites in Denmark and Germany more likely to quit smoking than those at the USA site.

# Supplemental Materials

Timeline

Description automatically generated

Figure Distributions of changes in CPD as a percentage of baseline smoking rates (n = 1783).

Chart, line chart

Description automatically generated

Figure Latent class mixture model BIC curve (n = 1783).

1. Department of Psychiatry, University of Vermont, Burlington, VT, USA

   2Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

   3 Department of Psychology, University of Bath, Bath, UK [↑](#footnote-ref-1)